Inventprise Unveils Promising COVID-19 Conjugate Vaccine Breakthrough

REDMOND, Wash., June 24, 2025 (GLOBE NEWSWIRE) -- Inventprise, a clinical-stage vaccine invention company, has announced a significant breakthrough in COVID-19 vaccination with the publication of a preclinical study in the Vaccine Journal that highlights its novel bivalent SARS-CoV-2 conjugate vaccine. This innovative vaccine, designed to offer broad protection against evolving COVID-19 variants, may provide long-term immunity, a critical advancement in the ongoing global battle against the virus.

The study, completed in late 2023, was initiated in 2022 and utilized Inventprise’s proprietary linker protein conjugation technology. This technology enhances vaccine immunogenicity by stimulating both arms of the immune system: B-cell (antibody-mediated) and T-cell (cellular) immunity. According to Ivan Olave, the Vice President of Viral Vaccines at Inventprise, the results underscore the potential of conjugate vaccine platforms not only for COVID-19 but also for various infectious diseases.

Unlike the widely utilized mRNA vaccines, which primarily elicit short-term antibody responses, the Inventprise conjugate vaccine aims to induce robust and sustained immunity. By conjugating a detoxified diphtheria-derived carrier protein (rCRM197) to the surface protein of both the SARS-CoV-2 Beta and Delta strains, expressed in Chinese Hamster Ovary (CHO) cells, the vaccine successfully generated strong immune responses in preclinical models.

Key findings from the study include: - Broad neutralizing antibody responses across up to five SARS-CoV-2 variants. - Evidence of both humoral and cellular immune activation, including the formation of memory T-cells. - Theoretical potential for longer-lasting protection, potentially reducing or eliminating the need for booster shots.

While the study did not fully confirm the long-lasting effects of immunity within its timeframe, preliminary data suggest the conjugate approach could effectively address the limitations associated with current mRNA-based vaccines, particularly regarding the duration of protection.

The implications of this research extend beyond individual health benefits; they also address global health equity concerns. Protein conjugate vaccines, already in use for diseases such as Haemophilus influenzae and pneumococcus, are known for their safety, scalability, and durability. Yves Leurquin, CEO of Inventprise, remarked, “This platform represents a sustainable path forward for equitable immunization, especially in settings where cold-chain requirements and booster logistics present major challenges.”

Looking ahead, Inventprise is actively seeking funding and partnerships to advance research on these groundbreaking findings and further define the duration of protection, as well as explore potential future applications. The company is also developing other lead vaccine candidates in clinical trials, including a 25-valent Pneumococcal Conjugate vaccine for adults and infants, alongside an IVT GBS-06 Hexavalent Group B Streptococcal Vaccine.

Founded in 2012 by Dr. Subhash Kapre, Inventprise is dedicated to developing high-valency vaccines aimed at protecting against global infectious diseases. The company, based in Redmond, Washington, and with a presence in Europe, leverages advanced research and development, state-of-the-art manufacturing, and proprietary PEG linker conjugation technology to create vaccines that are widely available and effective, particularly in low- and middle-income countries. For more information, visit [Inventprise](https://inventprise.com).